TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Liquid Biopsy

Liquid biopsy has the potential to revolutionize the cancer diagnosis and treatment market. Beyond clinical applications, liquid biopsies are already providing important information as part of drug development efforts. We believe liquid biopsy will be one of the most important growth areas in diagnostic tools in the coming decade.

What we’re watching:

  • Clinical data and validations
  • Reimbursement process
  • Biopharma partnership agreements
  • Progress of recent/pending commercial launches in asymptomatic screening and recurrence monitoring

Related themes:

Cowen Research Themes 2021

View the Handbook
1.5 Million

new cancer diagnoses in the U.S. each year


estimated current penetration of patients eligible to use liquid biopsy tools as a cancer companion diagnostic

>300 Million

people in the U.S. that could benefit from early cancer screening tools